Sustained Exendin-4 Secretion through Gene Therapy Targeting Salivary Glands in Two Different Rodent Models of Obesity/Type 2 Diabetes
Exendin-4 (Ex-4) is a Glucagon-like peptide 1 (GLP-1) receptor agonist approved for the treatment of Type 2 Diabetes (T2DM), which requires daily subcutaneous administration. In T2DM patients, GLP-1 administration is reported to reduce glycaemia and HbA1c in association with a modest, but significan...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396615/ |